long QT syndrome

long QT syndrome Long QT syndrome is a cardiac electrical disorder characterized by prolongation of ventricular repolarization that predisposes to torsades de pointes and sudden cardiac death. It may be congenital, caused by mutations in cardiac ion channel genes, or acquired from medications, electrolyte imbalances, or systemic disease. Recognition requires integration of clinical history, electrocardiography, and genetic testing to guide therapy including beta blockade, device therapy, and lifestyle modification.

Signs and symptoms

Patients typically present with transient loss of consciousness, palpitations, or seizure-like episodes during exertion, emotional stress, or sleep; these events may precede fatal arrhythmia. Prominent historical triggers include exercise, auditory stimuli, and sudden fright, and family histories often reveal unexplained sudden deaths. Symptoms overlap with presentations seen in reports involving Michael Jackson, Bruce Lee, Mary Shelley, James Dean, and other high-profile sudden deaths often discussed in cardiovascular case literature. Physical examination is often unremarkable, though some patients have syndromic features described in case series associated with Andersen–Tawil syndrome and Jervell and Lange-Nielsen syndrome cohorts managed at major centers such as Mayo Clinic and Cleveland Clinic.

Genetics and pathophysiology

Congenital forms result from pathogenic variants in genes encoding cardiac ion channels and accessory proteins, most commonly KCNQ1 and KCNH2 and less commonly SCN5A, reflecting the molecular substrate for repolarization. Mutations in these genes alter potassium or sodium currents, producing prolonged action potentials, early afterdepolarizations, and susceptibility to re-entrant polymorphic ventricular tachycardia. The genetic architecture includes autosomal dominant and autosomal recessive inheritance patterns with variable penetrance; founder mutations have been described in populations studied by institutions such as Harvard Medical School, Johns Hopkins Hospital, and Stanford University School of Medicine. Molecular mechanisms were elucidated in landmark studies from laboratories associated with Nobel Prize-winning research traditions, and genotype–phenotype correlations inform risk stratification developed in consortia including European Society of Cardiology and American College of Cardiology working groups.

Diagnosis

Electrocardiographic identification relies on measurement of the corrected QT interval (QTc) on a 12-lead ECG; diagnostic criteria combine QTc thresholds with clinical history and family history. Standard thresholds and scoring systems have been promulgated by guideline bodies such as the American Heart Association and the European Heart Rhythm Association. Provocative testing, ambulatory monitoring, and exercise testing are used to unmask concealed QT prolongation in evaluations at tertiary centers like UCSF Medical Center and Mount Sinai Hospital. Genetic testing panels target known LQTS genes and are interpreted in the context of variant classification frameworks from organizations like the American College of Medical Genetics and Genomics and expert consortia that include investigators from Boston Children's Hospital and Great Ormond Street Hospital.

Management and treatment

First-line therapy for congenital LQTS includes non-selective beta blockers such as propranolol and nadolol, with beta-blocker strategies advocated by societies including the Heart Rhythm Society. High-risk patients—those with prior cardiac arrest or recurrent syncope despite medication—are considered for implantable cardioverter-defibrillators (ICDs), with device management expertise centralized in centers like NewYork-Presbyterian Hospital and Massachusetts General Hospital. Left cardiac sympathetic denervation is a surgical option described in series from specialized units at Toronto General Hospital and Great Ormond Street Hospital. Management of acquired QT prolongation emphasizes withdrawal of offending drugs (lists maintained by regulatory agencies such as the U.S. Food and Drug Administration), correction of electrolytes, and avoidance of QT-prolonging medications during perioperative care at institutions like Johns Hopkins Hospital. Pregnancy management often involves multidisciplinary care teams from institutions including Brigham and Women's Hospital and Guy's and St Thomas' NHS Foundation Trust.

Prognosis and epidemiology

Congenital long QT syndrome prevalence estimates range from about 1 in 2,000 to 1 in 5,000, with variable expression across populations studied in registries maintained by consortia including the International LQTS Registry and national cohorts from Denmark, Japan, and the United States. Mortality risk is highest in untreated individuals with malignant variants; historical series from referral centers such as Rudolf Magnus Institute and Columbia University Irving Medical Center document substantial reductions in sudden death with contemporary therapy. Long-term outcomes depend on genotype, age at presentation, adherence to therapy, and access to specialist care at centers like Vanderbilt University Medical Center and Karolinska University Hospital. Public health efforts and regulatory oversight by agencies such as the European Medicines Agency aim to reduce acquired cases by monitoring drug safety and disseminating prescribing guidance.

Category:Cardiac arrhythmia